tirzepatide shortage over FDA says years-long is resolved, will give limited leeway to compounders Eli Lilly's Weight-Loss Drug Zepbound

Appetite Suppression: By acting on the brains appetite centers, semaglutide and tirzepatide promote a sense of fullness

Ligueros-Saylan, M., Foley, J

Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing

Lilly frames every compounder the same way in this letter